In Silico and In Vitro Studies on an Asymmetrical Porphyrin Derivative with Therapeutic Potential in Skin Disorders
-
Published:2024-05-27
Issue:6
Volume:17
Page:688
-
ISSN:1424-8247
-
Container-title:Pharmaceuticals
-
language:en
-
Short-container-title:Pharmaceuticals
Author:
Burloiu Andreea Mihaela1, Mihai Dragos Paul1ORCID, Manda Gina2ORCID, Lupuliasa Dumitru1, Neagoe Ionela Victoria2, Socoteanu Radu Petre3, Surcel Mihaela2, Anghelache Laurentiu-Iliuta2ORCID, Olariu Laura4, Gîrd Cerasela Elena1ORCID, Boscencu Rica1
Affiliation:
1. Faculty of Pharmacy, “Carol Davila” University of Medicine and Pharmacy, 6 Traian Vuia, 020956 Bucharest, Romania 2. “Victor Babeş” National Institute of Pathology, 050096 Bucharest, Romania 3. “Ilie Murgulescu” Institute of Physical Chemistry, Romanian Academy, 060021 Bucharest, Romania 4. SC. Biotehnos SA, 3-5 Gorunului, 075100 Bucharest, Romania
Abstract
For developing novel photosensitizers with therapeutic potential in non-malignant and malignant cutaneous disorders, the unsymmetrical porphyrin, 5-(2-hydroxy-3-methoxyphenyl)-10, 15, 20-tris-(4-carboxymethylphenyl) porphyrin, was evaluated in silico and in vitro. The cellular uptake of the investigated porphyrin and its ability to perform photodynamic therapy were investigated in terms of the viability, proliferation, and necrosis of human HaCaT keratinocytes and human Hs27 skin fibroblasts, in correlation with the predictions regarding diffusion through cell membranes, ADMET profile (absorption, distribution, metabolism, elimination, toxicity), and potential pharmacological mechanism. Molecular docking and 250 ns molecular dynamics simulations revealed that P5.2 has the potential to form a relatively stable complex with the carbonic anhydrase IX catalytic site, the lowest predicted free energy of binding (MM/PBSA) being −39.097 kcal/mol. The results of the in vitro study showed that P5.2 is incorporated within 24 h in the investigated cells, especially in HaCaT keratinocytes, indicating its photosensitizing ability. Nevertheless, P5.2 does not exert significant cytotoxicity in “dark” conditions. In turn, PDT induced a decrease in the number of metabolically active HaCaT keratinocytes within 24 h, accompanied by a 4-fold increase in lactate dehydrogenase release, indicating its ability to perform PDT in human skin cells. The experimental results suggest that the asymmetrical porphyrin is a promising candidate theranostics agent for skin disorders.
Funder
Romanian Ministry of Research, Innovation and Digitalization Nucleu “Carol Davila” University of Medicine and Pharmacy
Reference57 articles.
1. Recent advances in photosensitizers as multifunctional theranostic agents for imaging-guided photodynamic therapy of cancer;Sarbadhikary;Theranostics,2021 2. Tsolekile, N., Nelana, S., and Oluwafemi, O.S. (2019). Porphyrin as Diagnostic and Therapeutic Agent. Molecules, 24. 3. Plekhova, N., Shevchenko, O., Korshunova, O., Stepanyugina, A., Tananaev, I., and Apanasevich, V. (2022). Development of Novel Tetrapyrrole Structure Photosensitizers for Cancer Photodynamic Therapy. Bioengineering, 9. 4. Recent progress in photosensitizers for overcoming the challenges of photodynamic therapy: From molecular design to application;Zhao;Chem. Soc. Rev.,2021 5. Boscencu, R., Radulea, N., Manda, G., Machado, I.F., Socoteanu, R.P., Lupuliasa, D., Burloiu, A.M., Mihai, D.P., and Ferreira, L.F.V. (2023). Porphyrin Macrocycles: General Properties and Theranostic Potential. Molecules, 28.
|
|